Chistopher Soon, MD
Pathology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 18 years
- University of Hawaii John A. Burns School of Medicine, 2008
Offices
1 location · California Pacific Pathology Medical Group · 8 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp · Novato Community Hospital · Sutter Lakeside Hospital · Sutter Santa Rosa Regional Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Soon’s office at (415) 600-2200 to ask if they take your plan before you enroll.
California Medical Board record
Licence A109653 · Current
Licensed to practise in California · since 2009 · expires 2027-10-31 · University of Hawaii School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Sutter Lakeside HospitalLakeport, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Sutter Santa Rosa Regional HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.157, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sutter Lakeside Hospital
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 1 the same, 0 worse of 1 measures. Readmissions: 1 better, 5 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for COPD patientsComplications and deaths | 8.7 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 94 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 133 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 379 cases | None | Jul 2024 – Jun 2025 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 31 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.249 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 72 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -25.4 · 92 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -37.9 · 137 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 109 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.3) · 564 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 52 cases | No different | Jan 2024 – Dec 2024 |
What patients said (209 patients answered, 18% of those asked)
| Cleanliness | 5 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 83% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 70% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 82% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 63% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 58% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Sutter Santa Rosa Regional Hospital
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.157 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0.08 to 1.99) · 1,147 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.69 to 1.37) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.53 (108.3 to 216.76) · 54 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 316 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14 · 296 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,971 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.06 to 0.47) · 4,946 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 4,974 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.99 (2.93 to 7.06) · 1,288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0 to 3.15) · 532 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (0.82 to 3.9) · 1,214 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.87 (2.35 to 17.39) · 558 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.01 (4.29 to 11.73) · 522 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.14 to 3.05) · 337 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.89) · 4,064 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 206 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.626 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.299 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 342 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.1 · 184 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -14 · 352 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -17.4 · 309 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.2 · 309 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.2 (5.1 to 9.8) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8.8 to 15) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 215 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 100 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.8 to 18) · 1,275 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 702 cases | No different | Jan 2024 – Dec 2024 |
What patients said (752 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$200,690
Medicare paid this office $200,690 for 2,064 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Pathology examination of tissue using a microscope, intermediate complexity | 1,545 | $89,963 | $33 |
| Special stained specimen slides to examine tissue, each additional procedure | 349 | $26,250 | $24 |
| Special stained specimen slides to examine tissue, initial procedure | 509 | $19,939 | $31 |
| Pathology examination of tissue using a microscope, moderately high complexity | 133 | $17,980 | $75 |
| Special stained specimen slides to identify organisms including interpretation and report | 130 | $5,449 | $24 |
See all 27 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,545 | $89,963 | $33 |
| Special stained specimen slides to examine tissue, each additional procedure | 349 | $26,250 | $24 |
| Special stained specimen slides to examine tissue, initial procedure | 509 | $19,939 | $31 |
| Pathology examination of tissue using a microscope, moderately high complexity | 133 | $17,980 | $75 |
| Special stained specimen slides to identify organisms including interpretation and report | 130 | $5,449 | $24 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 71 | $5,393 | $75 |
| Microscopic genetic analysis of tumor, manual | 52 | $4,231 | $38 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 25 | $4,047 | $162 |
| Pathology examination of tissue using a microscope, high complexity | 20 | $3,321 | $133 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 21 | $3,126 | $35 |
| Pathology examination of specimen during surgery, first tissue block | 21 | $2,513 | $57 |
| Antibody evaluation, each additional single antibody stain procedure | 17 | $1,907 | $26 |
| Pathology examination of tissue using a microscope, moderately low complexity | 141 | $1,717 | $10 |
| Special stained specimen slides to examine tissue including interpretation and report | 82 | $1,594 | $10 |
| Cell examination of specimen, selective cellular enhancement technique | 60 | $1,535 | $24 |
| Evaluation of fine needle aspirate with interpretation and report | 20 | $1,468 | $64 |
| Pathology cytologic examination of specimen during surgery, initial site | 25 | $1,415 | $54 |
| Examination of archival tissue for genetic analysis | 70 | $1,170 | $17 |
| Evaluation of fine needle aspirate | 20 | $744 | $32 |
| Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | 21 | $651 | $31 |
| Genetic sequencing localization, initial procedure | 15 | $627 | $39 |
| Antibody evaluation, initial single antibody stain procedure | 17 | $556 | $31 |
| X-ray of surgical specimen | 19 | $483 | $14 |
| Preparation of tissue for examination by removing any calcium present | 29 | $459 | $11 |
| Pathology examination of specimen during surgery | 12 | $417 | $32 |
| Pathology examination of tissue using a microscope, limited examination | 93 | $409 | $4 |
| Pathology examination of tissue using a microscope | 11 | $62 | $6 |
Who their Medicare patients are
2,064 Original Medicare patients in 2024. Average age 74 · Under 65 5% · 85 and older 10% · Women 51% · Also on Medicaid 19% · Health risk score 1.17. At or below the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 66% · Coronary heart disease 23% · Diabetes 22% · Cancer 22% · Chronic kidney disease 19% · Atrial fibrillation 17% · Depression 16% · COPD 12% · Heart failure 11% · Stroke 6% · Dementia 4%.
The office billed $1,822,892, Medicare allowed $255,756 and paid $200,690; for 6,246 services of 40 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 2,064 | 6,246 | 74 | 1.17 | $1,822,892 | $200,690 |
| 2023 | 1,940 | 6,131 | 74 | 1.15 | $1,785,617 | $194,383 |
| 2022 | 1,921 | 6,222 | 74 | 1.16 | $1,801,545 | $191,828 |
| 2021 | 1,855 | 6,433 | 74 | 1.25 | $1,872,956 | $209,911 |
| 2020 | 1,244 | 5,093 | 73 | 1.42 | $1,482,035 | $174,943 |
| 2019 | 1,384 | 4,764 | 73 | 1.29 | $1,376,523 | $163,272 |
| 2018 | 1,160 | 3,612 | 73 | 1.35 | $1,031,286 | $127,321 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 27 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,452 | $82,148 | $32 |
| Special stained specimen slides to examine tissue, each additional procedure | 367 | $31,536 | $26 |
| Special stained specimen slides to examine tissue, initial procedure | 524 | $20,907 | $31 |
| Pathology examination of tissue using a microscope, moderately high complexity | 119 | $17,573 | $74 |
| Special stained specimen slides to identify organisms including interpretation and report | 129 | $5,719 | $23 |
| Microscopic genetic analysis of tumor, manual | 49 | $4,046 | $38 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 53 | $3,928 | $70 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 23 | $3,661 | $159 |
| Pathology examination of tissue using a microscope, high complexity | 26 | $3,572 | $132 |
| Pathology examination of specimen during surgery, first tissue block | 24 | $2,835 | $57 |
| Antibody evaluation, each additional single antibody stain procedure | 17 | $1,989 | $26 |
| Special stained specimen slides to examine tissue including interpretation and report | 97 | $1,762 | $11 |
| Pathology examination of tissue using a microscope, moderately low complexity | 159 | $1,686 | $10 |
| Pathology cytologic examination of specimen during surgery, initial site | 25 | $1,359 | $54 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 18 | $1,355 | $35 |
| Cell examination of specimen, selective cellular enhancement technique | 54 | $1,321 | $24 |
| Evaluation of fine needle aspirate with interpretation and report | 17 | $1,273 | $64 |
| Pathology examination of specimen during surgery | 20 | $869 | $32 |
| Examination of archival tissue for genetic analysis | 52 | $848 | $16 |
| Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | 27 | $800 | $29 |
| Genetic sequencing localization, initial procedure | 16 | $625 | $39 |
| Antibody evaluation, initial single antibody stain procedure | 17 | $615 | $32 |
| Evaluation of fine needle aspirate | 13 | $519 | $32 |
| Pathology examination of tissue using a microscope, limited examination | 81 | $381 | $4 |
| Preparation of tissue for examination by removing any calcium present | 24 | $380 | $11 |
| X-ray of surgical specimen | 16 | $356 | $14 |
| Pap test | 12 | $274 | $23 |
2022: 23 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,483 | $83,518 | $32 |
| Special stained specimen slides to examine tissue, each additional procedure | 382 | $31,817 | $25 |
| Special stained specimen slides to examine tissue, initial procedure | 590 | $22,285 | $31 |
| Pathology examination of tissue using a microscope, moderately high complexity | 107 | $13,177 | $70 |
| Microscopic genetic analysis of tumor, manual | 65 | $5,627 | $37 |
| Special stained specimen slides to identify organisms including interpretation and report | 145 | $5,585 | $22 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 54 | $3,980 | $71 |
| Pathology examination of tissue using a microscope, high complexity | 17 | $2,501 | $132 |
| Evaluation of fine needle aspirate with interpretation and report | 33 | $2,463 | $62 |
| Pathology examination of specimen during surgery, first tissue block | 20 | $2,315 | $56 |
| Special stained specimen slides to examine tissue including interpretation and report | 125 | $2,246 | $11 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 14 | $2,232 | $159 |
| Pathology examination of tissue using a microscope, moderately low complexity | 161 | $1,757 | $10 |
| Cell examination of specimen, selective cellular enhancement technique | 60 | $1,461 | $24 |
| Pathology cytologic examination of specimen during surgery, initial site | 22 | $1,287 | $56 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 16 | $1,202 | $34 |
| Evaluation of fine needle aspirate | 25 | $1,025 | $32 |
| Examination of archival tissue for genetic analysis | 51 | $822 | $16 |
| Genetic sequencing localization, initial procedure | 16 | $630 | $39 |
| Pathology examination of specimen during surgery | 16 | $582 | $31 |
| Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | 19 | $514 | $27 |
| Preparation of tissue for examination by removing any calcium present | 25 | $303 | $11 |
| Pathology examination of tissue using a microscope, limited examination | 66 | $248 | $4 |
2021: 24 services
| Pathology examination of tissue using a microscope, intermediate complexity | 1,447 | $82,156 | $34 |
| Special stained specimen slides to examine tissue, each additional procedure | 415 | $42,071 | $26 |
| Special stained specimen slides to examine tissue, initial procedure | 610 | $25,758 | $33 |
| Pathology examination of tissue using a microscope, moderately high complexity | 126 | $18,647 | $77 |
| Special stained specimen slides to identify organisms including interpretation and report | 140 | $6,879 | $24 |
| Microscopic genetic analysis of tumor, manual | 57 | $5,325 | $39 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 48 | $3,754 | $75 |
| Pathology examination of tissue using a microscope, high complexity | 23 | $3,425 | $137 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 12 | $1,986 | $165 |
| Cell examination of specimen, selective cellular enhancement technique | 75 | $1,963 | $25 |
| Pathology examination of specimen during surgery, first tissue block | 17 | $1,865 | $58 |
| Evaluation of fine needle aspirate with interpretation and report | 25 | $1,835 | $66 |
| Special stained specimen slides to examine tissue including interpretation and report | 102 | $1,755 | $11 |
| Pathology examination of tissue using a microscope, moderately low complexity | 130 | $1,471 | $10 |
| Pathology cytologic examination of specimen during surgery, initial site | 19 | $1,106 | $58 |
| Examination of archival tissue for genetic analysis | 61 | $1,061 | $17 |
| Genetic sequencing localization, initial procedure | 22 | $974 | $41 |
| Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | 27 | $728 | $27 |
| Evaluation of fine needle aspirate | 19 | $671 | $32 |
| Microscopic genetic analysis of tissue, computer-assisted technology, initial procedure, each multiplex procedure | 11 | $648 | $40 |
| Preparation of tissue for examination by removing any calcium present | 40 | $613 | $11 |
| X-ray of surgical specimen | 16 | $426 | $14 |
| Genetic sequencing localization, each additional procedure | 11 | $420 | $32 |
| Pathology examination of tissue using a microscope, limited examination | 47 | $195 | $4 |
2020: 27 services
| Pathology examination of tissue using a microscope, intermediate complexity | 850 | $52,243 | $35 |
| Special stained specimen slides to examine tissue, each additional procedure | 284 | $38,555 | $27 |
| Pathology examination of tissue using a microscope, moderately high complexity | 144 | $22,296 | $80 |
| Special stained specimen slides to examine tissue, initial procedure | 402 | $16,782 | $33 |
| Special stained specimen slides to identify organisms including interpretation and report | 109 | $5,568 | $25 |
| Microscopic genetic analysis of tumor, manual | 58 | $5,088 | $40 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 62 | $4,886 | $78 |
| Pathology examination of tissue using a microscope, high complexity | 23 | $3,471 | $139 |
| Special stained specimen slides to examine tissue including interpretation and report | 113 | $2,606 | $11 |
| Pathology examination of specimen during surgery, first tissue block | 28 | $2,594 | $59 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 14 | $2,393 | $171 |
| Evaluation of fine needle aspirate with interpretation and report | 28 | $2,308 | $68 |
| Cell examination of specimen, selective cellular enhancement technique | 73 | $1,917 | $25 |
| Pathology cytologic examination of specimen during surgery, initial site | 20 | $1,280 | $61 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 13 | $1,260 | $37 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 14 | $1,129 | $81 |
| Pathology examination of tissue using a microscope, moderately low complexity | 89 | $1,008 | $11 |
| Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | 30 | $978 | $33 |
| Examination of archival tissue for genetic analysis | 44 | $848 | $18 |
| Evaluation of fine needle aspirate | 17 | $736 | $35 |
| Genetic sequencing localization, initial procedure | 16 | $679 | $42 |
| Preparation of tissue for examination by removing any calcium present | 42 | $572 | $12 |
| Pathology examination of specimen during surgery | 11 | $483 | $35 |
| Pathology cytologic examination of specimen during surgery, each additional site | 12 | $444 | $37 |
| X-ray of surgical specimen | 17 | $381 | $14 |
| Pap test | 13 | $313 | $24 |
| Pathology examination of tissue using a microscope, limited examination | 47 | $206 | $4 |
2019: 25 services
| Pathology examination of tissue using a microscope, intermediate complexity | 916 | $55,512 | $35 |
| Special stained specimen slides to examine tissue, each additional procedure | 220 | $26,806 | $27 |
| Pathology examination of tissue using a microscope, moderately high complexity | 137 | $19,336 | $78 |
| Special stained specimen slides to examine tissue, initial procedure | 397 | $16,645 | $33 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 70 | $5,557 | $76 |
| Pathology examination of tissue using a microscope, high complexity | 36 | $5,241 | $138 |
| Pathology examination of specimen during surgery, first tissue block | 35 | $4,540 | $59 |
| Microscopic genetic analysis of tumor, manual | 48 | $4,390 | $39 |
| Evaluation of fine needle aspirate with interpretation and report | 51 | $3,903 | $66 |
| Special stained specimen slides to identify organisms including interpretation and report | 79 | $3,498 | $24 |
| Cell examination of specimen, selective cellular enhancement technique | 78 | $1,974 | $25 |
| Special stained specimen slides to examine tissue including interpretation and report | 95 | $1,906 | $11 |
| Pathology cytologic examination of specimen during surgery, initial site | 26 | $1,700 | $59 |
| Pathology examination of tissue using a microscope, moderately low complexity | 114 | $1,258 | $10 |
| Evaluation of fine needle aspirate | 28 | $1,255 | $34 |
| Examination of archival tissue for genetic analysis | 44 | $801 | $18 |
| Pathology examination of specimen during surgery | 16 | $763 | $33 |
| Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | 20 | $755 | $38 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 15 | $747 | $21 |
| Genetic sequencing localization, initial procedure | 12 | $490 | $41 |
| Pathology cytologic examination of specimen during surgery, each additional site | 12 | $467 | $36 |
| Pathology examination of tissue using a microscope, limited examination | 98 | $388 | $4 |
| Preparation of tissue for examination by removing any calcium present | 28 | $369 | $12 |
| X-ray of surgical specimen | 27 | $316 | $7 |
| Pathology examination of tissue using a microscope | 20 | $126 | $6 |
2018: 23 services
| Pathology examination of tissue using a microscope, intermediate complexity | 801 | $48,055 | $35 |
| Pathology examination of tissue using a microscope, moderately high complexity | 111 | $17,066 | $79 |
| Special stained specimen slides to examine tissue, each additional procedure | 138 | $13,239 | $27 |
| Special stained specimen slides to examine tissue, initial procedure | 283 | $11,496 | $33 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 56 | $4,632 | $76 |
| Special stained specimen slides to identify organisms including interpretation and report | 76 | $4,469 | $25 |
| Microscopic genetic analysis of tumor, manual | 47 | $4,352 | $42 |
| Pathology examination of tissue using a microscope, high complexity | 24 | $3,374 | $135 |
| Evaluation of fine needle aspirate with interpretation and report | 37 | $2,688 | $66 |
| Pathology examination of specimen during surgery, first tissue block | 26 | $2,581 | $60 |
| Cell examination of specimen, selective cellular enhancement technique | 87 | $2,286 | $25 |
| Special stained specimen slides to examine tissue including interpretation and report | 104 | $1,964 | $11 |
| Pathology cytologic examination of specimen during surgery, initial site | 20 | $1,259 | $60 |
| Pathology examination of tissue using a microscope, moderately low complexity | 102 | $1,222 | $11 |
| Evaluation of fine needle aspirate | 24 | $959 | $34 |
| Examination of archival tissue for genetic analysis | 33 | $650 | $19 |
| Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | 16 | $619 | $39 |
| Pap test, evaluation of fine needle aspirate, immediate, each additional evaluation episode | 15 | $612 | $21 |
| Pathology examination of specimen during surgery | 15 | $484 | $32 |
| Preparation of tissue for examination by removing any calcium present | 25 | $392 | $12 |
| Cell examination of body fluid, smears | 11 | $295 | $27 |
| X-ray of surgical specimen | 23 | $231 | $7 |
| Pathology examination of tissue using a microscope, limited examination | 37 | $155 | $4 |
Medicaid work
$19,742 in 2024
Medicaid paid $19,742 for 526 billed services this clinician did in 2024, up to 47 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| TISSUE EXAM BY PATHOLOGIST | 425 | $15,772 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 47 | $1,950 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 22 | $910 |
| TISSUE EXAM BY PATHOLOGIST | 18 | $574 |
| TISSUE EXAM BY PATHOLOGIST | 14 | $536 |
| 2024 | 526 | 5 | 47 | $19,742 |
| 2023 | 761 | 3 | 41 | $20,890 |
| 2022 | 900 | 4 | 50 | $20,422 |
| 2021 | 850 | 5 | 57 | $20,665 |
| 2020 | 419 | 3 | 30 | $9,327 |
| 2019 | 428 | 4 | 34 | $10,816 |
| 2018 | 329 | 2 | 27 | $4,833 |
See the largest Medicaid services in earlier years
2023
| TISSUE EXAM BY PATHOLOGIST | 660 | $17,518 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 89 | $3,180 |
| TISSUE EXAM BY PATHOLOGIST | 12 | $192 |
2022
| TISSUE EXAM BY PATHOLOGIST | 637 | $13,935 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 178 | $4,920 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 70 | $1,348 |
| TISSUE EXAM BY PATHOLOGIST | 15 | $219 |
2021
| TISSUE EXAM BY PATHOLOGIST | 554 | $12,158 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 167 | $4,712 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 101 | $2,664 |
| TISSUE EXAM BY PATHOLOGIST | 13 | $858 |
| TISSUE EXAM BY PATHOLOGIST | 15 | $273 |
2020
| TISSUE EXAM BY PATHOLOGIST | 320 | $7,064 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 77 | $2,014 |
| IMHCHEM/IMCYTCHM EA ADD ANTB | 22 | $249 |
2019
| TISSUE EXAM BY PATHOLOGIST | 338 | $6,838 |
| TISSUE EXAM BY PATHOLOGIST | 25 | $2,082 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 31 | $975 |
| TISSUE EXAM BY PATHOLOGIST | 34 | $921 |
2018
| TISSUE EXAM BY PATHOLOGIST | 316 | $4,564 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 13 | $269 |
Money from drug and device companies
$20 in 2019
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Keytruda | $20 | 1 payment
|
See the published payment
| Merck Sharp & Dohme | Meals · 2019-11-13 | Keytruda | $20 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 91.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1972838399
- Licence
- CA A109653California A109653: Current · expires 2027-10-31
- Trained
- University of Hawaii John A. Burns School of Medicine, 2008 · 18 years ago
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207ZD0900X (207ZD0900X)
- Mailing address
- 1024 Middle Ave, Apt C, Menlo Park, CA, 94025
- NPI first listed
- 2009-10-04
- NPI last updated
- 2016-11-28
This is when the NPI record was last certified, not a medical board exam.